+

WO2005117993A3 - Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers - Google Patents

Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers Download PDF

Info

Publication number
WO2005117993A3
WO2005117993A3 PCT/US2005/019630 US2005019630W WO2005117993A3 WO 2005117993 A3 WO2005117993 A3 WO 2005117993A3 US 2005019630 W US2005019630 W US 2005019630W WO 2005117993 A3 WO2005117993 A3 WO 2005117993A3
Authority
WO
WIPO (PCT)
Prior art keywords
efficacy
cancer
treatment
adenoviral vectors
improved safety
Prior art date
Application number
PCT/US2005/019630
Other languages
English (en)
Other versions
WO2005117993A2 (fr
Inventor
Thomas J Wickham
Masaki Akiyama
Selva Murgesan
David Einfeld
Tomoyuki Abe
Hiroshi Yoshida
Osamu Yamada
Hiromasa Araki
Original Assignee
Genvec Inc
Fuso Pharmaceutical Ind
Thomas J Wickham
Masaki Akiyama
Selva Murgesan
David Einfeld
Tomoyuki Abe
Hiroshi Yoshida
Osamu Yamada
Hiromasa Araki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc, Fuso Pharmaceutical Ind, Thomas J Wickham, Masaki Akiyama, Selva Murgesan, David Einfeld, Tomoyuki Abe, Hiroshi Yoshida, Osamu Yamada, Hiromasa Araki filed Critical Genvec Inc
Publication of WO2005117993A2 publication Critical patent/WO2005117993A2/fr
Publication of WO2005117993A3 publication Critical patent/WO2005117993A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode permettant de détruire les cellules tumorales dans la cavité péritonéale d'un mammifère. Ce procédé consiste à administrer au mammifère une dose d'un vecteur adénoviral à réplication déficiente comprenant (a) une séquence d'acide nucléique exogène codant pour un TNf-α humain, lié de manière fonctionnelle à un promoteur sélectif dirigé sur les cellules tumorales, (b) une protéine fibreuse présentant une disruption du site de liaison natif du récepteur CAR, et (c) une protéine base du penton présentant une disruption du site natif de liaison de l'intégrine.
PCT/US2005/019630 2004-06-04 2005-06-03 Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers WO2005117993A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711704P 2004-06-04 2004-06-04
US60/577,117 2004-06-04

Publications (2)

Publication Number Publication Date
WO2005117993A2 WO2005117993A2 (fr) 2005-12-15
WO2005117993A3 true WO2005117993A3 (fr) 2006-06-15

Family

ID=35463367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019630 WO2005117993A2 (fr) 2004-06-04 2005-06-03 Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers

Country Status (1)

Country Link
WO (1) WO2005117993A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115891A1 (fr) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Compositions d'adenovirus oncolytiques
WO2016054107A1 (fr) * 2014-09-29 2016-04-07 Counterpoint Biomedica Llc Orientation d'agents pharmaceutiques vers des zones pathologiques au moyen de polymères de fusion bifonctionnelle
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRIPE T.P. ET AL: "Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells", CANCER RESEARCH, vol. 61, 2001, pages 2953 - 2960, XP002969170 *
MIZUGUCHI H. ET AL: "CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice", GENE THERAPY, vol. 9, 2002, pages 769 - 776, XP002995191 *

Also Published As

Publication number Publication date
WO2005117993A2 (fr) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2015024667A8 (fr) Procédé pour augmenter l'expression de protéines codées par l'arn
WO2005086922A3 (fr) Adenovirus oncolytique dote de genes therapeutiques
WO2005071093A3 (fr) Porteurs de vaccin adenoviral de chimpanze
WO2007070392A3 (fr) Vecteurs d'expression adenovirale
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
GB0911870D0 (en) Optimised coding sequence and promoter
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
WO2008122811A3 (fr) Nouveaux vecteurs adénoviraux
WO2000055345A3 (fr) Therapie du cancer au moyen de cellules d'insectes contenant des genes codant un baculovirus recombinant
WO2003023000A3 (fr) Fragments d'adn lineaires destines a l'expression genetique
Markelc et al. In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: a study in a dorsal window chamber in mice
EP1455840A4 (fr) Traitement du cancer humain avec vector adenoviral tnf-alpha
WO2006050211A3 (fr) Therapie genique a base de proteine decarboxylase d'acide glutamique a administration peripherique pour lutter contre la douleur engendree par un traumatisme medullaire
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2007092944A8 (fr) Compositions et procedes impliquant une therapie de gene et une modulation de proteasome
WO2010086838A3 (fr) Vecteurs adénoviraux non ad5 et procédés et utilisations associés
WO2005117993A3 (fr) Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers
WO2008134752A3 (fr) Méthodes et compositions pour traiter le cancer
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
MX2021011039A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
EP4282490A3 (fr) Peptides de liaison de fibronectine ou tumorales destinés à être utilisés dans le diagnostic et le traitement d'une fibrose
Ternovoi et al. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
WO2005111204A3 (fr) Protéine de ligase de forssman porcine, adn complémentaire, organisation génomique et région de réglementation
WO2012010976A3 (fr) Variants de méganucléases clivant une séquence d'adn cible dans le gène tert et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载